Generex Biotechnology Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Generex Biotechnology Corporation
When the German major bought AskBio a couple of years ago, one of its assets was a gene therapy for Huntington’s, a devastating disease that leads to complete physical and mental deterioration. That asset, BV-101, is about to enter the clinic.
Deal Snapshot: Following its January AI discovery alliance with Exscientia, Sanofi will employ Atomwise’s platform technology against five undisclosed drug targets.
Public Company Edition: The stock market has been unkind to biotech firms but investors rewarded some drug developers for clinical trial successes, including Scholar Rock and Day One, which raised $205m and $172.5m, respectively. However, some SPAC deals and an IPO never got off the ground.
Boehringer Ingelheim tackles infringement activity pertaining to Trajenta and Jardiance in India, at least for now, but more action appears to be in the wings. The private German group remains confident that Jardiance will retain its preferred treatment choice status in the country for type 2 diabetes - but can the blockbuster therapy shake up the heart failure segment as well?
- Medical Devices
- Large Molecule
- Other Names / Subsidiaries
- Antigen Express, Inc.
- Grainland Pharmacy LLC
- Hema Diagnostic Systems, LLC
- Medisource Partners
- NuGenerex Distribution Solutions, LLC
- NuGenerex Immuno-Oncology
- Pantheon Medical
- Pantheon Medical – Foot & Ankle
- Regentys Corporation
- Veneto Holdings, LLC